What is already known about this topic?
On February 27, 2021, the Food and Drug Administration issued an Emergency Use Authorization (EUA) for the Janssen COVID-19 vaccine.

What is added by this report?
On February 28, 2021, after a transparent evidence-based review of all available data, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Janssen COVID-19 vaccine in persons aged ≥18 years for the prevention of COVID-19.

What are the implications for public health practice?
The Janssen COVID-19 vaccine has high efficacy against COVID-19–associated hospitalization and death. Persons may receive any ACIP-recommended COVID-19 vaccine and are encouraged to receive the earliest vaccine available to them. Use of all EUA-authorized COVID-19 vaccines is critical in controlling the pandemic.

  • Recommendation
  • Americas
  • United States of America
  • Janssen COVID-19 Vaccine
  • COVID-19